Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2024
FDA and EMA launch parallel scientific advice pilot program for complex generics
7 February 2024 - CDER’s Office of Generic Drugs and the EMA launched a voluntary pilot program to facilitate concurrent discussions ...
Posted by Michael Wonder on 22 Jan 2024
Generic drugs in the US are too cheap to be sustainable, experts say
19 January 2024 - Non-brand-name drugs are one inexpensive part of the healthcare system but they’re driving some manufacturers out of ...
Posted by Michael Wonder on 06 Dec 2023
Reimbursement to pharmacies for generic drugs by Medicare Part D sponsors
5 December 2023 - Pharmacy benefit managers (PBMs) manage prescription drug benefits on behalf of health insurers; PBMs negotiate reimbursements for ...
Posted by Michael Wonder on 11 Sep 2023
Generic drugs should be cheap, but insurers are charging thousands of dollars for them
11 September 2023 - Health insurers mark up prices of generics for cancer, multiple sclerosis and other complicated diseases. ...
Posted by Michael Wonder on 12 Jul 2023
Lupin Announces Health Canada approval of tiotropium bromide inhalation powder for treatment of COPD
11 July 2023 - Lupin announced that on 26 May 2023, its Canada subsidiary, Lupin Pharma Canada received approval from ...
Posted by Michael Wonder on 07 Jul 2023
A priority review voucher program to fuel generic drug development
6 July 2023 - Millions of Americans report that they are unable to fill their prescriptions or are not taking their ...
Posted by Michael Wonder on 14 Feb 2023
NATCO files generic olaparib tablets in US
13 February 2023 - NATCO Pharma announces submission of abbreviated new drug application containing a paragraph IV certification with the ...
Posted by Michael Wonder on 26 Jan 2023
A “method of use” to prevent generic and biosimilar market entry
25 January 2023 - A critical pathway that generics and biosimilars manufacturers have used to circumvent patent thickets has been “skinny ...
Posted by Michael Wonder on 08 Jan 2023
JAMP Pharma Group receives Health Canada approval for JAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes
6 January 2022 - The JAMP Pharma Group is pleased to announce the Health Canada approval of JAMP Sitagliptin, a generic ...
Posted by Michael Wonder on 02 Jan 2023
Mark Cuban’s cost plus drug company continues to revolutionise generic drug pricing
1 January 2023 - Mark Cuban's Cost Plus Drug Company is making waves again, as it steadily raises its profile ...
Posted by Michael Wonder on 07 Dec 2022
An innovation surcharge to fund the repurposing of generic drugs
10 November 2022 - The use of generic drugs continues to increase, generating substantial savings for purchasers and improving affordable access ...
Posted by Michael Wonder on 29 Sep 2022
Europe's generic drugmakers say they may cut output due to energy bills
28 September 2022 - Europe's drugmakers have warned they may stop making some cheap generic medicines because of surging electricity ...
Posted by Michael Wonder on 09 Sep 2022
Bausch Health responds to Norwich Pharmaceuticals tentative FDA approval for a 200 mg rifaximin
9 September 2022 - Bausch Health and its gastro-enterology business Salix Pharmaceuticals today responded to the US FDA's tentative approval ...
Posted by Michael Wonder on 17 Aug 2022
Akorn announces FDA has approved generic cetrorelix acetate
16 August 2022 - Akorn announces that it received FDA approval for a generic version of cetrorelix acetate 250 mcg ...
Posted by Michael Wonder on 15 Aug 2022
A doctor says a patient saved over $1,000 a month by ordering prescriptions through Mark Cuban’s online pharmacy
14 August 2022 - Deena Kishawi, an OB-GYN resident physician in Chicago, was reviewing the medication of one of her patients ...